Vicarious Surgical Inc. (NYSE:RBOT – Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 309,143 shares, a growth of 120.1% from the December 31st total of 140,432 shares. Based on an average trading volume of 266,613 shares, the short-interest ratio is currently 1.2 days. Approximately 5.2% of the shares of the stock are sold short. Approximately 5.2% of the shares of the stock are sold short. Based on an average trading volume of 266,613 shares, the short-interest ratio is currently 1.2 days.
Vicarious Surgical Price Performance
Shares of NYSE RBOT traded up $0.13 on Friday, hitting $2.21. The company’s stock had a trading volume of 68,429 shares, compared to its average volume of 177,188. The stock has a 50 day moving average of $2.50 and a 200-day moving average of $5.15. The company has a market capitalization of $14.48 million, a price-to-earnings ratio of -0.24 and a beta of 1.52. Vicarious Surgical has a 12-month low of $1.80 and a 12-month high of $16.35.
Vicarious Surgical (NYSE:RBOT – Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($1.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.37) by $0.46. Sell-side analysts expect that Vicarious Surgical will post -10.89 EPS for the current fiscal year.
Institutional Trading of Vicarious Surgical
Analyst Upgrades and Downgrades
RBOT has been the subject of a number of recent analyst reports. BTIG Research reissued a “neutral” rating on shares of Vicarious Surgical in a report on Friday, December 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vicarious Surgical in a research note on Wednesday, January 21st. Finally, Wall Street Zen downgraded shares of Vicarious Surgical from a “hold” rating to a “sell” rating in a report on Saturday. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $7.00.
Read Our Latest Report on RBOT
About Vicarious Surgical
Vicarious Surgical develops a next-generation robotic surgical system that integrates virtual reality (VR) with minimally invasive instrumentation. Its flagship offering combines ultra-slender, articulated robotic arms with a VR surgeon console, allowing physicians to perform laparoscopic procedures with enhanced precision, dexterity and visual immersion. The platform is designed to reduce patient trauma compared with traditional open or laparoscopic surgery and to expand surgeon access to challenging operative sites.
The company’s technology is intended for use across multiple surgical specialties, including general surgery, gynecology and urology.
Featured Articles
- Five stocks we like better than Vicarious Surgical
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Vicarious Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicarious Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
